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Extracellular vesicles (EVs) and their cargo represent an intriguing source of cancer biomarkers for developing robust and sensitive
molecular tests by liquid biopsy. Prostate cancer (PCa) is still one of the most frequent and deadly tumor in men and analysis of EVs
from biological fluids of PCa patients has proven the feasibility and the unprecedented potential of such an approach. Here, we
exploited an antibody-based proteomic technology, i.e. the Reverse-Phase Protein microArrays (RPPA), to measure key antigens and
activated signaling in EVs isolated from sera of PCa patients. Notably, we found tumor-specific protein profiles associated with
clinical settings as well as candidate markers for EV-based tumor diagnosis. Among others, PD-L1, ERG, Integrin-β5, Survivin, TGF-β,
phosphorylated-TSC2 as well as partners of the MAP-kinase and mTOR pathways emerged as differentially expressed endpoints in
tumor-derived EVs. In addition, the retrospective analysis of EVs from a 15-year follow-up cohort generated a protein signature with
prognostic significance. Our results confirm that serum-derived EV cargo may be exploited to improve the current diagnostic
procedures while providing potential prognostic and predictive information. The approach proposed here has been already applied
to tumor entities other than PCa, thus proving its value in translational medicine and paving the way to innovative, clinically
meaningful tools.
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INTRODUCTION
Prostate cancer (PCa) is still the second cause of cancer-related
male deaths in highly developed countries [1]. A significant
fraction of PCa patients arrives at diagnosis with advanced forms,
while others retain indolent tumors which will never progress into
aggressive stages [2, 3]. Therefore, an accurate, early diagnosis is
likely to improve the outcome and the quality of life of PCa
patients while reducing the over-treatment [4].
Extracellular vesicles (EVs) are membrane-enclosed bodies in
the nano- to micro-meter scale that are secreted by nearly all cells
and shuttle their biological content as a means of cell-to-cell
communication [5, 6]. Tumor cells are now recognized to release
more EVs than their normal counterpart and tumor-derived EVs
can be easily isolated from bodily fluids [7–10], thus offering an
exquisite source in terms of biomarkers and, mechanistically, of
cancer treatment strategies [11–13]. The EV sub-population in the
range of 30–150 nm in diameter is referred to as exosomes and
has been shown to actively transport DNA, proteins, long and
small RNAs [11, 14] as well as small peptides, such as prions [15].
Different from other vesicles, which are generated by random
shedding mechanisms or from dying cells by discharge, exosomes
drive intra- and inter-tissue cross-talk [16–18], are involved in
physiological tissue homeostasis and immune system regulation
[11] and in processes [12, 19, 20] that are often aberrant in tumors
[7]. In this regard, PCa is characterized by multiple genomic lesions
[21] and several variants seem to be associated with tumor
development [22, 23]. Therefore, the EV cargo in PCa patients
could be a promising source of new biomarkers [24] that deserve
intense investigation.
The importance of better classifying patients into risk-
progression categories has given impetus to the identification of
prognostic biomarkers [21]. However, the available diagnostic
tools for PCa therapy remain far from satisfying. The application of
mass spectrometry-based proteomics has provided insights into
the clinical management of PCa [25]. However, the limitations, in
terms of sensitivity, throughput and clinical applicability of mass
spectrometry, leave margins for other methodologies [25–27].
Here, by using an antibody-based technique, i.e. the Reverse-
Phase Protein microArrays (RPPA), we evaluated the proteomic
content of EVs isolated from blood sera of PCa tumors, healthy
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donors, patients with hypertrophic disease, and post-prostatectomy
disease-free cases. A retrospective cohort with 15-year follow-up
was further included for defining the prognostic value of
biomarkers. Our results confirm and expand upon the concept
that EVs shuttle cancer-related biomarkers and provide a useful
platform for diagnostic as well as prognostic purposes. The
combined proteomic and EV-based liquid-biopsy approaches used
herein advocate for the use of new, non-invasive cancer monitoring
tools in the personalized treatment of PCa.
RESULTS
Use of RPPA technology as a proteomic approach to analysis
of EV cargo
We and others have already shown that the RPPA technology is a
powerful biomarker discovery platform for the analysis of EV
protein cargo [28, 29]. Therefore, we decided to leverage on our
previous findings to further investigate the analytical performance
of a combined RPPA-EV approach. To this end, we first selected
suitable cell line models and isolated EVs by differential
ultracentrifugation of conditioned culture medium (Fig. S1A).
Analysis by Scanning and Transmission Electron Microscope (SEM
and TEM, respectively) showed that the majority (90%) of enriched
EVs ranged from 34 to 100 nm (Fig. 1A, B). RPPA and Western
Blotting analyses showed that such isolated EVs expressed
transmembrane and cytosolic proteins that are typically enriched
in exosomes [30] (Fig. S1B, C). As a specificity test we selected the
epithelial cell adhesion molecule (EpCAM) [31, 32] since it is a
reference marker in circulating cancer cell capture approaches and
is used to search for disseminated tumor cells in bone marrow
biopsies [33]. In this regard, we used two lung cancer cell lines, i.e.
H1975 and H1299, that are positive and negative for EpCAM,
respectively [34, 35] (Fig. S1D). Western blotting and TEM
Immunogold labeling confirmed that EVs isolated from H1975
and H1299 paralleled the expression of EpCAM in their parent cells
(Fig. S1E and Fig.1C). In order to test the limit of detection of the
RPPA platform, we measured EpCAM in scaling mixtures of H1299-
and H1975-derived EVs. EpCAM RPPA levels positively correlated
with the percentage of H1975-derived EVs and were still
detectable over the background down to as low as 3% of H1975
EVs (Fig. S1F). Furthermore, we selected HT29, an EpCAM+ colon
cancer line [36] (Fig. S1G) and the metastatic cell lines LNCaP and
PC3, positive and negative for EpCAM, respectively (Fig. S2A).
Similar to what we found in lung cancer cell lines, we successfully
measured EpCAM by RPPA in scaling mixtures of EVs isolated from
either HT29 and H1299 (Fig. S1H) or LNCaP and PC3 (Fig. S2B),
both showing detectable expression over the background down
to 3% of positive EVs. To expand upon the concept of using RPPA
as a sensitive biomarker discovery platform for low-abundance
antigens or proteins expressed by low-frequency cancer sub-
clones [37], we studied the expression of two markers, IL-6 and
TGF-β, reportedly shuttled in EVs and over-expressed in advanced
cancers [6, 24]. TGF-β and IL-6 were differentially expressed in PC3
and LNCaP cells (Fig. S2A), and resulted undetectable in EVs by
Western blotting (data not shown). Conversely, RPPA analysis of
LNCaP- and PC-derived EVs, mixed in scaling percentages, showed
that TGF-β and IL-6 expression in EVs mirror the pattern found in
parent cells (Fig. S2C, D). Notably, when measuring TGF-β by RPPA
in EVs isolated from PC3 cells along with a cytokine reference
standard, we were able to detect down to as low as 7 pg/mL of
TGF-β in PC3-derived EVs (Fig. S2D).
Besides merely testing the analytical performance of RPPA, we
were particularly interested in measuring post-translational
modifications, e.g. phosphorylation, of proteins shuttled by EVs.
To this end, we evaluated the expression of the epithelial-growth
factor receptor (EGFR) and one of its phosphorylated forms
(EGFR_pY1068) in A431, an epithelial squamous carcinoma cell
line, and in human PCa-derived activated fibroblasts (CAFs).
Indeed, EGFR is expressed at high levels by A431 (1–2 ×106
receptors per cell [38, 39]) while being low to undetectable in
fibroblasts [40]. EVs were isolated from culture media and mixed in
scaling percentages for RPPA analysis. As expected, the levels of
EGFR were proportional to the percentage of A431 in each mixture
point (Fig. S2E) while those of PD-L1, reportedly expressed by both
A431 and CAFs [41, 42], did not follow a dilution curve (Fig. 2E). In
line with the expression of its total content counterpart, RPPA
levels of phosphorylated EGFR (EGFR_pY1068) positively corre-
lated with the fraction of A431 in mixed A431/CAFs EVs (Fig. S2F).
Driven by these results, we sought to quantify the levels of
EGFR_pY1068 in scaling mixtures of A431 and CAFs as well as of
their isolated EVs using a reference curve of a synthetic
EGFR_pY1068 peptide, ranging from the nanogram down to the
picogram scale. Interestingly, although cell-derived extracts
displayed significantly higher amounts, RPPA expression of
EGFR_pY1068 was still detectable below the picogram range in
sample mixtures with increasing fractions of A431-derived EVs
(Fig. 1D). Even though the sensitivity and specificity may depend
on both the individual antibody performance and antigen relative
expression, our data soundly suggest that the proposed approach
is feasible and robust.
Validation of RPPA results by an ELISA-based assay
In order to validate and integrate RPPA with orthogonal
approaches, we set up a homemade ELISA (enzyme-linked
immunosorbent assay), hereafter referred to as ELEXO. In such an
assay, EVs are directly coated to the plastic plate and are
subsequently probed for the expression of different surface
markers by using primary and HRP-conjugated secondary
antibodies followed by colorimetric detection (Fig. 2A). Thus,
we took advantage of ELEXO to measure EpCAM and the
exosomal marker CD81 on EVs isolated from H1975 and H1299.
Similar to our previous RPPA and Western blot analyses, EpCAM
levels were significantly detectable over the background only in
H1975-derived EVs (Fig. 2B). EVs isolated from HT29 and SW480
colorectal cancer cell lines express CD81 and display differential
levels of EpCAM by Western Blotting (Fig. S3A) as well as by
ELEXO (Fig. S3B). Subsequently, we focused on the clinically
relevant antigen PD-L1 [43] and, in order to test the antibody
specificity, we transduced 293T cells with either empty (TWEEN)
or PD-L1 gene (PD-L1) lentiviral vectors, respectively. We then
isolated EVs from relative culture media and successfully
measured PD-L1 by ELEXO only on those deriving from PDL-1-
transduced cells (Fig. S3C). In addition, since both H1975 and
H1299 cells express PD-L1 (Fig. S3D) we used ELEXO to confirm
the presence of PD-L1 on their secreted EVs (Fig. S3E). Similar
results were obtained by RPPA analysis of PD-L1 levels on a series
of matched cells and cell-derived EVs including H1975 and
H1299 samples (Fig. S3F).
Encouraged by these results, we envisioned an EV-based
liquid-biopsy approach [44] built on RPPA analysis of EVs isolated
from cancer patients’ serum samples. The majority of isolated
vesicles (85%) showed sizes ranging between 34 and 100 nm as
by SEM and TEM analyses (Fig. 2C–E and Fig. S4A). Analysis of
typical exosome markers [45–47] confirmed their expression in
EVs derived from sera of a small set of healthy donors,
hypertrophic disease and PCa samples by Western blotting
(Fig. S4B). Similarly, we measured exosomal proteins by RPPA in
EVs isolated from a set of 12 PCa samples (Fig. S4C). Then we
used ELEXO to evaluate EpCAM levels in EVs isolated from the
serum of 7 colon adenocarcinoma (CRC) samples (Table S1). Our
results showed that EpCAM is not only expressed by colon
tumors [31, 32], but also a potential biomarker for CRC-derived
EVs (Fig. 2F). Since PD-L1 is a predictor biomarker of immu-
notherapy response in advanced Non-Small-Cell lung cancer
(NSCLC) [48], we sought to apply ELEXO to detect PD-L1 in serum
EVs isolated from 6 NSCLC samples (Table S1, Fig. 2G), thus
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confirming the clinical applicability of ELEXO. Parallel to the
above experimental design on cell line models, we tested the
possibility to use RPPA to measure, via a reference dilution curve,
the levels of EGFR_pY1068 in EVs isolated from the serum of
primary NSCLC and CRC samples (n= 35) (Table S1). Our results
show that, although not quantifiable, EGFR_pY1068 is still
detectable above the background even below the picogram
level (Fig. 2H) suggesting the opportunity for accurate measure-
ment of phosphorylated and non-phosphorylated analytes in
serum-derived EVs.
Fig. 1 Isolation and RPPA testing of cell line-derived EVs. A Representative images of EVs purified from conditioned medium of H1975 and
H1299 cells by Scanning and Transmission Electron Microscopy (SEM and TEM) analyses, upper and lower panels, respectively. The images
shown are representative of all cell lines used in the article. B Boxplots representative of H1975 and H1299 EVs size distribution evaluated by
SEM analysis. The lower schematic representation exemplifies the size distribution of EVs. C EpCAM antigen evaluated in EVs purified from
cultures of H1975 and H1299 by Immuno-Electron Microscopy (IEM). D RPPA measurement of absolute amounts of EGFR_pY1068 in A431 and
fibroblasts. Whole cell and EV lysates were first diluted to a total protein concentration of 0.5 mg/ml and then printed as mixtures with
the indicated decreasing and increasing fractions of A431 and fibroblasts, respectively. A dilution curve of EGFR_pY1068 synthetic peptide in
the plotted range, was printed along with cell line and EV samples and provided a reference curve (lower-left panel) to predict absolute
concentrations of EGFR_pY1068 in A431 and fibroblast mixtures (upper panel). Data in the left side of the upper panel represent a
magnification of the low picogram range from the adjacent (right) scatterplot. Main points represent the mean of technical replicates (n= 3,
empty symbols behind each main-colored point). The reference curve in the lower panel has been used to predict EGFR_pY1068 absolute
levels in samples via simple linear regression (red line) of log10-converted triplicates of normalized RPPA levels from the
EGFR_pY1068 synthetic peptide dilution curve. Adjusted r squared, regression formula and p-value are shown inside the reference curve plot.
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Fig. 2 Orthogonal validation of RPPA results on serum-derived EVs. A Representative scheme of our homemade ELISA test, i.e. ELEXO,
including EV-coated microtiter plate, primary antibody, HRP-conjugated secondary antibody and colorimetric reaction with TMB substrate.
B H1975 and H1299 EVs analyzed by ELEXO assay. IgG isotype and Phosphate-Buffered Saline (PBS) were used as internal controls. Data are
reported as mean and SD (n= 3) of arbitrary units of O.D. (Optical Density) at the specified wavelength (nm) (*p= 0.02). C, D Representative
images of SEM (C) and TEM (D) analysis of EVs isolated from the sera of prostate cancer patients. Images are representative of pivotal and
training cohort PCas. E Box plot representative of serum EV size distribution evaluated by SEM analysis. F, G ELEXO measurement of EpCAM (F)
and PD-L1 (G) antigens in EVs isolated from colon and lung cancer patients, respectively. CD81 has been used as endogenous EV control. Data
are reported as mean and SD (n= 3) of arbitrary units of O.D. (Optical Density) at the specified wavelength (nm). Internal reference controls
were reported as IgG, CD-81, EpCAM, or PD-L1 antibody in PBS condition. H Absolute RPPA quantification of EGFR_pY1068 synthetic peptide
in dilution curve along with isolated EVs from sera of colon and lung cancer patients. The expression levels in EVs fall below the lowest
EGFR_pY1068 peptide dilution point and their scale is magnified in the left panel of the plot. The reference curve in the lower panel was
obtained as in Fig. 1D to predict absolute EGFR_pY1068 RPPA levels in EV samples.
M. Signore et al.
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Pivotal analysis on a cohort of PCa patients
Inspired by the results obtained by RPPA and ELEXO on EVs
derived from cell lines and cancer patients’ sera, we designed a
series of study sets tailored to PCa and graphically depicted in
Fig. 3A. First, we conducted a RPPA experiment on the
restricted set of patients referred to as ‘pivotal cohort’,
composed only of PCa patients and healthy individuals (HD)
(Fig. 3A). Surprisingly, we found that analysis of serum-derived
EVs using as low as thirty-seven proteins, selected by their
relevance in oncological processes (Fig. S4D), is per se sufficient
to infer sample origin (Fig. 3B and Fig. S5A). Hierarchical
clustering of RPPA data confirmed that such EV-based
proteomic analysis differentiates PCa from HD (Fig. 3C). In
particular, ERG (ETS-related gene), PD-L1, Survivin, Integrin-β5,
IL-6 and SPARC were significantly altered in tumoral EVs
(Fig. 3D). Prospectively, RPPA analysis of key EV (phospho-)
proteins such as those involved in the EGFR, mechanistic target
of rapamycin (mTOR) and vascular endothelial growth factor
receptor (VEGFR) pathways, allow cancer- and patient-specific
adoption of treatment strategies (Fig. 3E, F).
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It is worth noting that ERG protein over-expression is under
investigation as surveyor genomic aberration for the application of
novel diagnostic tools in PCa [49]. Along similar lines, PD-L1,
Survivin and Integrin-β5 have already been found in vesicles
isolated from cancer patients [48–51], SPARC, STAT3 and activated
EGFR (EGFR_pY1173), have been described as predictors of
response to targeted therapy [52–54] while IL-6 is known to
promote prostate tumorigenesis and progression to aggressive-
ness [52, 55]. Indeed, soluble serum protein components such as
IL-6 may eventually contaminate the EV cargo following the
differential ultracentrifugation steps [56]. Therefore, we devised an
ad hoc experimental design and analyzed a cytokine panel by
Luminex technology on two paired samples obtained from the
same preparation of serum-derived tumoral EVs. In details, we
collected 100 μg of EVs left un-lysed in the supernatant from
the last-ultracentrifugation step (SN), likely containing contami-
nant proteins, along with an identical total protein content
(100 μg) from EVs lysed in RIPA buffer (lysed- RIPA) and likely
containing residual, membrane-bound contaminants as well as
proteins from the EV cargo. While other cytokines were still
present in the both samples, IL-6 resulted higher in the RIPA-lysed
preparation (Fig. S4E, F). These results suggest that, although
soluble serum proteins may still be an undesired contaminant of
the EV preparation by differential ultracentrifugation, in our hands
the IL-6 levels measured by RPPA are likely to derive mainly from
the EV cargo.
In search of further confirmation on the importance of the
differentially expressed targets emerging from our RPPA
analysis, we evaluated the levels of mRNAs corresponding to
selected RPPA antigens (Fig. 3D) in publicly available PCa
datasets (https://www.cbioportal.org/ [21] and http://gepia.
cancer-pku.cn/index.html [57]). Although tissue mRNA expres-
sion represents an analytical and molecular scenario potentially
different from released EVs, still we found that half of our RPPA
PCa markers were upregulated at the mRNA level when
comparing tumor tissues with their normal adjacent counterpart
(Fig. S5B, C). Overall our results and, although partial, such
additional in silico data, strengthen the idea of integrating the
available molecular profiling with proteomic analysis of EVs for
identifying tumor-specific marker and druggable targets for
improvement of patient’s outcome.
Evaluation of EV protein cargo as a diagnostic tool in PCa
In order to expand upon and confirm our preliminary experi-
mental evidence on the pivotal cohort, we analyzed a larger
patient set, hereafter referred to as the “training cohort” (Fig. 3A)
and composed of: (i) healthy donors (HD); ii) over twelve months
disease-free patients (DF); iii) hypertrophic cases (Hyper) and iv)
tumors (PCa) (Table S1). Following enrichment by differential
ultracentrifugation, EVs isolated from PCa sera showed higher
total protein content if compared to HD and DF groups while
Hyper showed levels close to those of PCa patients (Fig. S5D). The
panel of RPPA endpoints analyzed in the training was enlarged
with respect to the pivotal cohort and comprised total and
phosphorylated antigens involved in diverse hallmark cancer
signaling pathways (Fig. S6). To better define key disease-specific
markers, we compared PCa to each of the other groups (i.e. either
Hyper or DF or HD) and found significantly different antigens
exclusive of individual comparison sets as well as those shared
between all the aforementioned comparisons (Fig. 4A, Tables S2–
4). Subsequently, we searched for diagnostic candidates based on
their individual performance in the ROC curve analysis of PCa
versus controls (grouped HD and Hyper). Intriguingly, phospho-c-
Myc_T58/S62 and phospho-TSC2_Y1571 emerged as the best
candidates and, although their combination resulted in a modest
gain of diagnostic power, it might still be of clinical relevance in
the context of PCa (Fig. 4B). Graphical representation of the data
showed that, compared to controls, at least half of the PCa had
lower phospho-c-Myc_T58/S62 combined to higher phospho-
TSC2_Y1571 (Fig. 4C). Notably, these results held true even when
comparing PCa to the HD group alone (Fig. S7A). Among key
endpoints reaching statistical significance in all comparison sets
(i.e. PCa versus either Hyper or DF or HD), we found components
and interactors of the MAP-kinase/mTOR pathway [58] such as
TGF-β, phospho–β-Catenin_T41/S45 (β-Catenin_pT41/pS45) and
phospho–c-Myc_T58/S62 itself (Fig. 4A and Tables S2–4, gray
boxes), eventually underlying a common aberrant pathway route
(Fig. S7B). In addition, several RPPA endpoints emerged as
significantly altered or shared when including all available paired
comparison sets (i.e. each group versus each of the others)
(Fig. S7C).
Interestingly, for a subset of the proteins analyzed in the
training, we reproduced the differential expression pattern
obtained in the pivotal cohort. In detail, high levels of SPARC
were significantly associated with PCas while an increase in PD-L1
and Survivin characterized both inflammatory and neoplastic
disease (Fig. S7D). Although ERG did not reach statistical
significance in the training cohort, a subgroup of PCa showed
elevated (above the 65th percentile) ERG expression and likely
associated with high-risk patients as well as with evidence of
progression within 3 years (Fig. S8A). Conversely, while in the
pivotal cohort IL-6 emerged as a differentially expressed antigen
(PCa versus HD), in the training cohort the levels of IL-6 showed a
modest, not significant trend of correlation with increasing
pathological Tumor-Node-Metastasis (pTNM) staging (Fig. S8B).
Intrigued by this result, we sought to correlate key proteomic EV
markers with standard clinical parameters such as prostate-
specific antigen (PSA) levels and pTNM. While PSA levels in PCa
Fig. 3 RPPA study sets and results on the pivotal cohort. A Schematic representation of the experimental study design. The cohorts assayed
comprise a (i) pivotal group of primary prostate cancer (PCa) and healthy donor (HD) samples that have been utilized for experimental setup,
i.e. EV isolation and RPPA sensitivity tests, (ii) training cohort including PCa, hypertrophic (Hyper), post-prostatectomy-disease-free (DF) cases
as well as healthy donor (HD) EV samples and used to confirm and expand upon the RPPA analysis of the pivotal cohort in search of diagnostic
markers, iii) a set of two independent cohorts of PCa samples used for risk assessment and prognostic marker evaluation, respectively. The risk
assessment cohort comprises samples with 15-year documented follow-up (recurrent and non-recurrent). The prognostic marker evaluation
cohort is composed of forty primary cell lines established from patients with bad and good documented prognosis [66]. B Principal
component analysis (PCA) of 37 RPPA endpoints measured in EV samples from the pivotal cohort (16 healthy donor, HD, and 12 tumors, PCa).
PCA algorithm employed the covariance matrix obtained from normalized RPPA intensity values. Scores (i.e. samples) are represented as dots
(HD, green) and squares (PCa, red) while loadings (i.e. RPPA antibodies) are overlaid and pointed by gray arrows. C Two-way unsupervised
hierarchical clustering of the same dataset as in (B). Normalized RPPA intensity values were pre-standardized (Z score) and the color intensity
scale indicates high (yellow), average (black) and low (cyan) relative expression. D Scatterplots of selected statistically significant RPPA
endpoints, resulting from comparison of HD- and PCa-derived EVs. Statistical significance by Student’s t test is reported on each plot and
coded with asterisk(s) based on the level of significance (*p <= 0.05, **p <= 0.01, ***p <= 0.001). E, F Two-way unsupervised hierarchical
clustering on selected panels of significant RPPA endpoints (p <= 0.05) associated with growth factor receptor signaling and angiogenesis
(respectively E, F). Statistical significance was calculated by comparing normalized RPPA intensity values of HD and PCa, as in (D). Hierarchical
clustering was performed on standardized RPPA data as in (C) and Z scores are color-coded as high (yellow), average (black) and low (cyan).
M. Signore et al.
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Fig. 4 Group comparisons and biomarker analysis on the training cohort. A Combined Up Set [94] and volcano plots, with color-coded
annotations of diverse RPPA endpoint sets that characterize specific binary comparisons of sample groups. The vertical histogram (upper
panel) reports the relative frequency of unique (single dots) and shared (connected dots) significant RPPA antibodies resulting from three
specific sets of statistical comparisons, namely PCa versus Hypertrofic, HD and Post-prostatectomy disease free (DF), respectively. The volcano
plot in the lower panel shows fold-changes (log2) versus significance [−log10(p - value)] for all analyzed comparison sets (i.e. PCa versus
Hypertrofic or HD or disease-free, respectively). The color-coding (‘queries’) of RPPA antibody labels in the volcano plot matches
the corresponding colors sets in the main frequency histogram. The horizontal histogram adjacent to comparison sets (left-bottom part of the
upper panel) shows the absolute frequency of statistically significant RPPA antibodies obtained for each individual set. B Univariate ROC curve
analysis of two selected, significant candidate markers resulting from statistical comparison of controls (grouped HD plus Hypertrophic
diseases) and tumors (upper plots). The diagnostic performance of combined top-scoring candidates was further assessed by ROC curve
analysis (bottom plot). All plots report the AUC value along with the 95% confidence interval as well as p, optimal cut-off, sensitivity and
specificity values. C Bivariate plot of best candidates (c-Myc T58/S62 and TSC2 Y1571) normalized RPPA intensity values in the analyzed cohort
comprising tumors (PCa) and control samples, i.e. HD and Hypertrophic diseases, the latter subdivided into Adenoma and Inflammatory
diseases, being the category ‘others’ referred to grouped non-neoplastic samples (controls). The ellipses represent the probability of
distribution (95% confidence under normality assumption) for the two main comparison groups, namely PCa and others.
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and benign prostatic hyperplasia largely overlap at a range of
4–10 ng/ml [59], in such a gray zone we found, for a few of the
analyzed markers, that a fraction of PCa samples was distinguish-
able from hypertrophic diseases in terms of RPPA expression
levels (Fig. S8C, D). Furthermore, a restricted number of RPPA
endpoints displayed a correlation trend with pTNM as well as with
pTNM and PSA (Fig. S8E).
Overall, the RPPA analysis of EV protein content revealed a set
of cancer-specific biomarkers and demonstrated that a targeted
liquid-biopsy approach allows discrimination of patients from
healthy individuals. Our data suggest that combination of
proteomic analysis of EVs with conventional clinical parameters
may prove useful for early cancer detection.
Targeted analysis of EVs proteome as prognostic and
monitoring tool in PCa
Due to the relatively high life expectancy of diagnosed patients,
the PCa risk management is a fundamental research field [60]. To
identify biomarkers that are predictive of the risk of progression,
we studied a retrospective cohort (Risk Assessment, Fig. 3A, Table
S5) comprehensive of six advanced castration-resistant (CR)
patients as reference controls. Serum samples were collected
before surgery for the 19 primary tumor cases and during the
recurrence phase for the advanced CR patients. Isolated EVs
underwent RPPA profiling and, interestingly, high-risk and
advanced tumors showed shared expression of several antigens
(Fig. S9A). Therefore, in order to find a common signature, we
grouped high-risk patients with advanced tumors and compared
them to low/intermediate-risk cases (Fig. 5A). Moreover, we
compared high-risk patients alone to either advanced PCa or
low/intermediate-risk cases (Fig. S9B, C). The differentially
expressed antigens characterizing the high-risk and advanced
PCa patients and comprising components of the cell cycle, PI3K,
WNT, and MAPK pathways, likely reflect the higher frequency of
genomic alterations found in aggressive forms [21]. Indeed,
mining of publicly available PCa tissue dataset [21] confirmed an
increased number of mutations in advanced forms, both at the
pathway and at the gene level, if looking at the genes
corresponding to the differentially expressed RPPA endpoints
(Fig. S9D, E). Then, we investigated the association between RPPA
antigen levels and the frequency of recurrence in the retro-
spective, i.e. Risk Assessment, cohort (Fig. 3A). Seven out of 19
Fig. 5 Analysis of EV-based prognostic RPPA biomarkers. A Bar chart of log2 fold-change (log2FC) of grouped high-risk and advanced PCa
(red) versus low-/intermediate-risk (green) patients for all significantly different RPPA endpoints analyzed by Wilcoxon rank-sum test. Statistical
significance reported for each bar is coded with asterisk(s) based on the level of significance (*p <= 0.05, **p <= 0.01, ***p <= 0.001). B Two-
way unsupervised hierarchical clustering of the 13 significantly different (p <= 0.05) RPPA endpoints emerging from statistical comparison of
non-recurrent (pink, n= 11) and grouped recurrent and advanced tumor (gray, n= 13) EV samples. One sample was excluded due to lacking
follow-up information. C Scatterplots of ERG expression resulting from comparison of low/intermediate-, high-risk and advanced (Adv. PCa)
tumors by RPPA analysis. Recurrent patients were indicated by an asterisk (*). The plots represent distribution of RPPA intensity values, and the
line indicates an arbitrary baseline. Statistical comparisons were performed as described in the methods section.
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primary cases–with the exclusion of one sample lacking a
documented follow-up–developed metastases over a 15-year
time frame (Table S5). Intriguingly, heatmap with significantly
different RPPA endpoints showed that the non-recurrent cases
converged into a separate cluster when compared to grouped
recurrent cases and advanced tumors (Fig. 5B), advocating for
potential prognostic implications of such an analytical approach.
Along these lines and similar to the strategy used to individuate
the best diagnostic candidates in the training cohort, we
performed statistical comparisons and ROC curves and found
RPPA targets that may allow for EV-based discrimination of
recurrent cases and advanced forms. In particular, phospho-c-
Myc_T58/S62, phospho-SHC_Y317 and Wnt5a/b as well as
phospho–c-RAF_S338 and TGF-β reached statistical significance
and emerged as optimal prognostic candidates (Fig. S10A and Fig.
S10C, individual antigens). Advanced PCa has the propensity to
metastasize to bone and, notably, TGF-β mRNA over-expression is
associated with tumor invasion and spreading to bones [61].
Therefore, we investigated a publicly available dataset (GEO
GSE74685 [61]) and found that, consistently with our results
obtained in EVs (Fig. S10C), the levels of tissue mRNAs for genes
corresponding to RPPA candidates, i.e. c-Myc, SHC-1, Wnt5a, c-
RAF-1 as well as TGF-β, were increased in bone metastases as
compared to all other metastatic sites (Fig. S10D). We then asked
whether any combination of these five antigens could gain
prognostic and predictive value over individual ROC curves. Of
note, the concomitant random expression of almost three out of
the five candidate RPPA endpoints at levels beyond their
respective cut-offs, was able to produce a significantly improved
prognostic signature (Fig. S10C, Score). Again, we sought to
corroborate our results by analysis of mRNA levels of the
corresponding genes from publicly available gene expression
datasets, namely [21] and [62]. When comparing metastatic and
primary PCa samples, only Wnt5a/b was significantly and
congruently upregulated in both datasets (Fig. S10E), suggesting
that our data and EV-based approach provide complementary
information to standard tissue transcriptomic characterization.
Interestingly and similarly to what we have shown here for the
pivotal and training sets and others have already shown [63, 64],
we observed ERG protein expression beyond the calculated cut-off
(i.e. over-expressed) in high-risk patients (Fig. 5A) and in low- and
high-risk categories (Fig. 5C). Of note, elevated ERG protein
expression in recurrent patients (Fig. 5A) mirrored gene expression
data from two public datasets (GEO GSE32269 [62] and GSE74685
[61], Fig. S10F, G, respectively), whereby ERG over-expression has
been shown to parallel the genomic fusion and to contribute to
PCa progression by WNT and MAPK signaling activation [61].
Finally, to confirm the prognostic relevance of the data, we took
advantage of gene expression profiling (Affymetrix arrays) on the
ex vivo collection of primary PCa cultures (n= 40, Prognostic
Marker Evaluation, Fig. 3A) from patients with 10-year documen-
ted clinical follow-up [65, 66]. Gene panels enriched in primary
cells derived from recurrent and non-recurrent cases were
assigned either bad or good prognosis, respectively (Fig. S11A).
Surprisingly and in line with our RPPA results, cells obtained from
patients with poor prognosis displayed mRNA upregulation for
the genes corresponding to significant prognostic RPPA candi-
dates, i.e. TGFΒ1, WNT5A/B, SHC1, RAF1 and MYC (Fig. S11A, B).
Western blotting analysis confirmed the over-expression of
candidates in cells deriving from cases with poor prognosis
(Fig. S11C). Overall, these data corroborate the hypothesis that an
EV-based protein signature may have a clinically valuable
prognostic significance.
DISCUSSION
Shreds of evidence have shown that EVs are an important source
of cancer biomarkers [67]. Since for many cancers the amount of
vesicles circulating in patients’ biological fluids is acceptedly
increased as compared to healthy individuals, the analysis of EV
proteomic patterns [25] may provide a valuable strategy to
complement current liquid-biopsy technologies, such as circulat-
ing tumor cells or DNA (ctDNA) analysis.
Here, we used the RPPA platform for multiplexed, high-
throughput analysis of protein cargo in cancer-derived EVs. We
first tested the sensitivity and specificity of this approach for
the detection of selected proteins in EVs isolated from
commercially available cancer cell lines. In particular, EpCAM
expression was analyzed in EVs by RPPA assay and furtherly
validated by immunogold electron microscopy and Western
blotting.
Commercially available ELISA assays for EVs are based on EV
immune-capture or lysate analysis [27, 68]. Here, we devised a
new homemade ELISA assay, i.e. ELEXO, as both an additional
validation platform and a potential alternative to RPPA for rapid
translation to the clinics of a low-throughput quantification assay
for surface EV antigens.
To date, blood PSA screening is the sole non-invasive test for
PCa diagnosis. In addition, among patients with elevated
serum PSA levels (≥3–4 ng/mL) and undergoing a standard
transrectal ultrasound-guided biopsy, the chance of detecting
PCa is approximately 30–40% [69]. Consequently, there is an
urgent need for fast and multiparametric diagnostic tests
based on non-invasive methods and requiring low amounts of
patients’ sample. In this regard, we conceived a pilot study on
EVs isolated from a small cohort of PCas and found that a
proteomic repertoire of as low as 37 antigens allows for the
discrimination of tumors from healthy individuals. Interest-
ingly, among the differentially expressed antigens found by us,
IL-6 has already been described as a tumor-discriminating
antigen in PCa [70], while high levels of PD-L1, Integrin-β5 and
Survivin upregulation seems to correlate with cancer survival
and aggressiveness [50, 51, 71, 72]. Subsequently, we extended
the proteomic analysis to EVs isolated from a larger PCa cohort
(training) including healthy donors and hypertrophic patients
as control groups as well as post-prostatectomy disease-free
patients as an additional comparative group. Again, based on
the sole analysis of EV content, we found a proteomic
signature capable of distinguishing tumors from controls. Of
note, the set of differentially expressed endpoints include key
players in cancer signaling networks. In particular, phosphor-
ylation of β-catenin at T41-S45 determines its nuclear, trans-
activating activity [73], TSC2 phosphorylation (Y1571) associ-
ates with mTOR signaling activation [58, 74] and, intriguingly,
the latter is coupled to low phospho-c-Myc_T58/S62, i.e.
reduced c-Myc degradation rates [75, 76]. The cartoon
depicted in Fig. S7B exemplifies an hypothetical aberrant
network flow, whereby i) an increased inhibitory phosphoryla-
tion of phospho–TSC2_Y1571 activates mTORC1 signaling, ii)
augmented phospho-c-Abl_T735, directly relating to its
sequestration into the cytoplasm by 14–3–3 proteins, pro-
motes TGF-β activity [77] and iii) SEK1 phosphorylation favors
metastatic spreading.
While pTNM and Gleason score are critical parameters to
establish the risk of recurrence [78], their prognostic value
remains poor leaving a clinical gap in the identification of PCas
that have an intrinsic tendency to progress. Therefore, we
studied a retrospective cohort, with 15 years of documented
follow-up, to identify EV proteins indicative of tumor aggres-
siveness. Patients from this cohort were stratified into low/
intermediate- and high-risk cases and were analyzed together
with a group of advanced tumors. Intriguingly, ERG over-
expression correlated with advanced PCa forms and high-risk
cases as well as with recurrence. High-risk and advanced PCas
shared the expression of diverse proteins that are reportedly
associated with cancer progression, namely TGF-β [79], Wnt5a/b
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[34, 35, 80], Shc1 (phospho-SHCY317) [28], phospho-c-RAF-S338
and phospho-c-MycT58/S62 [81]. Moreover, we validated our
results by measuring the expression of corresponding candidate
genes on a collection of patient-derived immortalized cells [66]
and confirmed the correlation between increased mRNA levels
and a documented poor prognosis.
Since the management of PCa patients is currently under
heated debate [82, 83], our predictive molecular signature may
provide the opportunity to discriminate risk categories, improve
the accuracy and feasibility of early diagnosis and suggest a
potential monitoring method for suitable assignment of active
surveillance protocols, nerve-sparing conservative surgery as well
as radical treatments.
Although our data deserve further validation in dedicated,
independent studies, the integration of the proteomic analysis of
EVs with other available clinical and molecular parameters may
lead to next-generation, multiparametric liquid-biopsy assays, thus
providing a novel tool for screening, diagnosis, and risk
assessment of PCa as well as of other cancers.
MATERIALS AND METHODS
Patient recruitment
The study design is outlined in Fig. 3A and clinical data were reported in
Table S1. More specifically, a pivotal cohort composed of 12 primary
prostate tumors and 16 healthy donors were used as technical proof of
principle. The training cohort was composed of (i) 57 diagnosed primary
tumors with 3-year clinically documented follow-up, (ii) 41 hypertrophic
patients, (iii) 44 cases enrolled at least 12 months follow-up after
prostatectomy and negative for recurrence or residual disease, and (iv)
18 age-matched healthy donors. A retrospective, risk assessment cohort
(15-year follow-up; Table S5) including 19 tumor patients for prognostic
marker estimation as well as 7 recurrent and 11 non-recurrent patients
(and one additional patient with non-documented follow-up).
PCa patient stratification was performed by considering D’Amico risk
categories [84], and ISUP/WHO 2016 classification, but arbitrarily stratifying
cohorts as follows: Low risk: Gleason =6 and pTNM ≤ T2a; Low/Intermediate
risk: Gleason ≤ 7(3+ 4) and pTNM= T2b-2c; High risk: Gleason= 7(4+ 3)
and pTNM= T2c and all Gleason score cases with pTNM ≥ T3a. Cohorts
were enrolled before COVID-19 pandemic. [pTNM: pathological Tumor-
Node-Metastasis (pTNM). The NSC-lung cancer and colorectal tumor cohort
clinical data were reported in Table S1.
EV separation
EV isolation was optimized as previously described [28] and following the
MISEV2018 guidelines [30] Cell lines were cultivated in recommended
medium and FBS (Fetal bovine serum) starved before EV concentration and
processed with round of centrifugation as follows. Cell conditioned-starved
medium was centrifuged 5minutes at 1200 rpm after 72 h. The super-
natants transferred in new tubes and centrifuged again for 15minutes at
13300 rpm. Supernatants were transferred in clean tubes and ultracen-
trifuged (Beckman Coulter, Brea, CA) 2 h at 110,000g (RCF). All centrifuga-
tion steps were performed at 4 °C temperature. (Beckman Coulter Optima-
LE-80K-Ultracentrifuge; Rotor: BECKMAN SW41). Pellets were washed once
and resuspended in 40 μl of phosphate buffer saline (PBS). The
concentration of EV suspension was measured by Bradford assay. 5 ml of
peripheral blood from participants were collected in serum clinical tubes
(Code-367955-DBdiagnostics). Sera were collected and centrifuged
5minutes at 1200 rpm for serum separation and stored at −80 °C. 1 ml
of serum for patient was used to obtain about 100–300 total μg of EVs.
General patient exclusion criteria: patients with blood viral infection and
different kind of tumors. For EVs separation, sera were thawed, transferred
in clean tubes and diluted in PBS to reach equal volume of 1.4 ml. They
were centrifuged 5minutes at 1200 rpm, the supernatants transferred in
new tubes and centrifuged again for 15minutes at 13,300 rpm. Super-
natants were transferred in clean tubes and ultracentrifuged (Beckman
Coulter, Brea, CA) 2 h at 160,000g (RCF). All centrifugation steps were
performed at 4 °C temperature. (Sorvall-Ultracentrifige WX90-Ultra series,
SN 42071706, ASHI; Rotor F50L-24×1.5). Pellets were washed once and
resuspended in 40 μl of phosphate buffer saline (PBS). The concentration
of EV suspension was measured by Bradford assay.
Reverse-phase Protein microArrays
Reverse-Phase Protein microArrays (RPPA) were already optimized
[28, 85]. Briefly, all PBS-resuspended EV samples were lysed in a TPER
(Thermo Fisher Scientific)-based lysis buffer for 30 minutes on ice. EV
lysates were properly diluted and then printed in triplicate spots on
nitrocellulose-coated glass slides (GRACE Bio-Labs, Bend, OR) using an
Aushon 2470 equipped with 185 μm pins (Aushon Biosystems, Billerica,
MA), according to the manufacturer’s instructions at a concentration of
0.5 mg/ml and 0.125 mg/ml. Reference standard lysates, comprised of
HeLa + Pervanadate (BD, Franklin Lakes, NJ), Jurkat + Etoposide (Cell
Signaling, Danvers, MA), Jurkat + Calyculin A (Cell Signaling), A431+
Pervanadate (Santa Cruz Biotechnologies) and A431+ EGF (BD, Franklin
Lakes, NJ) were printed in 10-point dilution curves as procedural controls
and positive controls for antibody staining. Each reference was printed in
triplicate at concentrations of 0.5 mg/ml and 0.125 mg/ml. Per-spot
protein concentration was evaluated by Sypro Ruby Protein Blot Stain
(Invitrogen, Carlsbad, CA). Immediately prior to antibody staining,
printed slides were treated with 1x ReBlot Mild Solution (Merck Millipore,
Darmstadt, Germany) for 15 min, washed 2 × 5 min with PBS (Invitrogen)
and incubated for 2 h in blocking solution (2% I-Block, (Applied
Biosystems, Foster City, CA), 0.1% Tween-20 in PBS). Immunostaining
was carried out using an avidin-biotin complex (ABC) signal amplification
kit (DAKO, Carpinteria, CA). Primary antibody binding was detected using
a biotinylated goat anti-rabbit IgG H+ L (1:7500) (Vector Laboratories,
Burlingame, CA) or rabbit anti-mouse IgG (1:10) (DAKO) followed by
biotin amplification and streptavidin-conjugated IRDye680LT fluoro-
phore (LI-COR Biosciences, Lincoln, NE). Primary antibodies against total
and phosphorylated protein targets, were previously validated for single-
band specificity by Western Blot using cell lysates (see Supplementary
File 1). Negative control slides were incubated with secondary antibody
alone. All Sypro and immunostained slides were scanned using a Tecan
Power Scanner™ (Tecan Group Ltd, Switzerland). Acquired images were
analyzed by MicroVigene v5.2 (VigeneTech, Carlisle, MA) software for
spot detection, local background subtraction, negative control subtrac-
tion, replicate averaging, and total protein normalization. Throughout
the manuscript and in the figures, the above-described normalized RPPA
data are referred to as normalized RPPA intensity or levels and are
expressed in arbitrary units (A.U.).
Electron microscopy
For Scanning Electron Microscopy (SEM) analysis, purified EVs were left to
adhere to polylysine treated round glass coverslips (10mm) for 4 h at RT
and then fixed with glutaraldehyde 2,5% in sodium cacodylate buffer 0.1 M
overnight at 4 °C. Samples were washed, post-fixed with 1% OsO4 in 0.1M
sodium cacodylate buffer for 1 h at RT and dehydrated through a graded
series of ethanol solutions (from 30% to 100%). Ethanol was gradually
substituted by a 1:1 solution of hexamethyldisilazane (HMDS) and absolute
ethanol for 30min, successively by pure HMDS for 1 h (RT). Samples were
completely dried by removing the HMDS and leaving at RT for 2 h. Dried
samples were mounted on stubs, coated with gold (20 nm) and analyzed in
a FE-SEM Quanta Inspect F (FEI, Thermo Fisher Scientific). (Shively and
Miller, 2009).
For Transmission Electron Microscopy (TEM) purified EVs from cell-
conditioned supernatants or serum were analyzed by negative staining
method according to [86, 87] with slight modifications. Briefly, samples
were let to adsorb on 400mesh carbon-coated grids for 10min, blotted by
filter paper and air dried. An ammonium molybdate 4% and phospho-
tungstic acid 2% (50% v/v) contrasting solution (pH 6.8) was added for 20 s
to each sample and blotted by filter paper. Samples were examined at
100 kV by Philips EM208S TEM (FEI - Thermo Fisher Scientific), equipped
with the Megaview II SIS camera (Olympus).
EV TEM images were analyzed by iTEM software to collect the diameter
size of more than 100 vesicles for each sample. Only vesicles more than
20 nm in diameter were taken into account and the EV size distributions
were expressed in a box plot.
Immuno-Electron Microscopy (IEM) was performed on extracellular
vesicles adsorbed on carbon coated grids prepared as previously
described for TEM negative staining. Grids were floated side down on a
drop of PBS buffer and successively transferred on a drop of anti-EpCAM
monoclonal antibody (Santa Cruz) (1:5 in PBS) over night at 4 °C. Then,
samples were rinsed on PBS drops and incubated on 10nm gold-
conjugated goat anti-mouse IgG serum (SIGMA) (1:30) for another 2h.
Finally they were rinsed and stained by an ammonium molybdate 4% (pH
6,8) and phpsphotungstic acid 2% solution (50% v/v). The excess fluid
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was blotted by filter paper and grids were air dried and observed Philips
EM208S TEM (EI –ThermoFisher).
Cytofluorimetric and Western blot assay
Flow cytometric analysis. Cancer cell lines (100,000 cells/tube) were
incubated with antibodies against EpCAM (Miltenyi, Biotec, Custom
antibody) and PD-L1 (XP version, Cell Signaling Danvers, MA) for 1 h on
ice. Anti-IgG1 antibody was used as negative control (Abcam, Cambridge,
UK). After 3 washes in PBS, samples were incubated with PE- or FITC-
conjugated secondary antibodies for 1 h on ice. FACS analysis was
performed by FACS-Canto instrument (BD, Becton-Dickinson, Franklin
Lakes, NJ, USA).
Western blotting. EVs were resuspended in RIPA lysis buffer and
incubated for 15minutes in ice. TPER (Thermo Fisher Scientific)-based
lysis was used for sera EVs. Samples were centrifuged at 16,000 x g and
supernatants were collected and transferred in a clean tube. After Bradford
assay, EV lysates were diluted in LDS sample buffer (Thermofisher
Scientific, Massachusetts, USA) at total amount of 40μg. Samples were
loaded and run into a 4–12% polyacrylamide gel (Thermofisher Scientific,
Massachusetts, USA) and transferred on nitrocellulose filters (SDS-PAGE)
that were subsequently incubated with anti-EpCAM and anti-CD81 (Santa
Cruz Biotechnology, California, USA) antibodies at 4 °C overnight. TSG101
and CD81 antibodies were used following relative datasheets Abcam and
Santa Cruz. Then, filters were incubated with HRP-conjugated secondary
anti-mouse or rabbit antibody (Southern Biotech, Birmingham, USA) for 1 h
and signals detected with ECL method (GE Healthcare, Piscataway
Township, NJ) by Chemidoc XRS system (Bio-Rad, Hercules, CA).
Homemade ELISA ‘ELEXO’
EVs were resuspended in PBS (50μl) and deposited in a 96well-plate (Nunc,
Milan, IT) at final concentration of 10 µg/well and incubated for coating for
2 h at 37 °C (or over-night). After the coating, three washes in PBS were
performed. Coated plate was treated with blocking solution [PBS with 0.5%
BSA (Bovine Serum Albumin pure protein); the solution was filtered with
0.200 μm pores] for 2 h. Primary Antibody staining was performed in PBS
solution and incubated for 1 h at room temperature while secondary
antibody (anti-mouse-HRP-conjugated antibody; Southern Biotech, Bir-
mingham, USA) was diluted in PBS/0.5% BSA solution for 1 h at room
temperature. Anti-PD-L1 (86744-Cell Signaling Technology, Danvers, MA),
anti-IgG1 (Abcam, Cambridge, UK), anti-CD81 Mab and anti-EpCAM Mab
(Miltenyi Biotec, USA; Custom antibody) were used at final concentration of
2 μg/ml. The plate was washed 3 times in PBS after each antibody
incubation. After washing, the color-developing reaction with TMB
(Thermoscientific, Massachusetts, USA) was started and then stopped with
H2SO4. Optical densities were measured at 450 nm by Victor X3 (Perkin
Elmer, Massachussets, USA). The blocking solution and the working
antibody concentrations were optimized to minimize background staining
with a relative scalar dilution of the reagents (i.e. BSA, primary and
secondary antibodies).
Luminex assay
100 μg of EVs were lysed in 50 μl of standard RIPA buffer [(20 mM Tris-
HCl pH7.2150 mM NaCl;1% NP40 (Igepal CA-630); Distilled water to
volume; Proteases-inhibitors)] and diluted 1:4 in PBS for the analysis.
100 μg of parental EVs were left, non-lysed (SN), in 50 μl in the buffer
(PBS) of the last step of Ultracentrifugation and was directly analyzed by
Luminex. Cytokine/chemokine quantification in EV extracts and in EV
(SN) was achieved by xMAP technology through a Luminex platform
(Bio-Rad Laboratories, Hercules, CA, USA) equipped with a magnetic
washer workstation according to the manufacturer’s protocol. RIPA
(dilute 1:4 in PBS) and PBS buffer were used as background controls.
Samples were analyzed using a human magnetic Luminex assay (R&D
Systems, Minneapolis, MN, USA). Brain-Derived Neutrophil Factor
(BDNF), CCL11, Fibroblast Growth Factor 13 (FGF-13), IL-5, IL-4, IL-23,
IL-6, MMP-2 (membrane-matrix-metalloprotease-2), beta-Nerve Growth
Factor (beta-NGF), N-regulin-1 beta1/NRG-1, Tumor Necrosis Factor
alpha (TNF-α), Interferon gamma-induced protein 10 (CXCL10), Inter-
feron gamma (IFN-γ), IL-2, IL-8/CXCL8, IL-17/IL-17A, CCL-2/MCP-1 and
Vascular Endothelial Growth Factor (VEGF) were analyzed. The quanti-
fication was carried out with a Bio-Plex array reader (Bio-Plex 200
System) and Bio-Plex Manager (Version 6.1 Bio-Rad Laboratories,
Hercules, CA, USA) software.
Statistical analysis and data representation
Protein analyses in EV samples. Student’s t or non-parametric Wilcoxon
rank-sum tests were used for continuous variables to analyze the
differences between groups. A p-value ≤ 0.05 was considered statistically
significant. Furthermore, the receiver operating characteristic (ROC)
method was used in order to find possible optimal cut-offs of the
biomarkers capable of splitting patients into groups with different
outcomes probabilities. Statistical analyses were conducted indepen-
dently by means of SPSS® (v21.0) and MedCalc® (v10.0.1) or ‘R’ [88]. Data
standardization (scaling), followed by two-way hierarchical clustering
(Euclidean distance and Ward’s method was used if not specified
elsewhere), were performed by means of JMP v11 (SAS Institute, Cary,
NC) or ‘R’ [88] and RStudio [89]. Principal component analysis (PCA) as
well as most data represented throughout the manuscript was
independently reproduced by means of ‘R’ using the following packages:
base, methods, utils, stats, graphics, grDevices, tcltk, openxlsx, tidyverse
[90], data.table, RColorBrewer, reshape2, reshape, readxl, FactoMineR,
factoextra, grid, gridExtra, circlize, cluster, dendextend and Complex-
Heatmap [91].
Analysis of publicly available datasets. Messenger RNA results from
Taylor’s tissue dataset (NCBI GEO accession code GSE21032) have been
accessed through the Prostate Cancer Genomics Data Portal (http://
cbioportal/) and combined with reported clinical data. Wilcoxon/Kruskal
Wallis was used to analyze the differences between groups. GraphPad
Prism v4 and JMP v11 (SAS Institute, Cary, NC) were used to perform
statistical analyses.
Cell lines, PCa-derived cells and gene expression profiling
(Affymetrix)
Cell cultures. All cell lines were obtained by ATCC. All cells were used as
precocious (six passages) frozen stocks after arrival. They are routinely
tested for Mycoplasma contamination (“PCR mycoplasma test kit”, product
no. A3744, PanReac AppliChem) before EV preparations. H1299, HT1975,
HT29 cells were cultivated as recommended protocols. SW480 line was
maintained in RPMI and 10% of Fetal Bovine Serum (FBS). A431 and
293T cells were cultivated in DMEM (Dulbecco’s Modified Eagle’s Medium)
with 10% of FBS, Glutamine (Gln) and Penicillin–Streptomycin (P/S) at
standard doses. 293T cells were stable transduced with TWEEN vector [92]
empty (Control) or with PD-L1 gene. Sequence-verified cDNA encoding for
human PD-L1 was purchased from Dharmacon, cut with XbaI and EcoRV
and inserted into TWEEN vector. It was kindly provided by Dr.Valeria
Coppola. (PD-L1 Human-MGC Human CD274 Sequence-Verified cDNA-
Clone ID: 30915301-Catalog Number: MHS6278-202856825)
(Lentiviral manipulation authorized by Ministry of Health rules. RM/IC/
Op2/17/002.notifica I.5.i.s/2017/15 - Biotecnologie. D.L.vo 206/2001). PC20
cancer activated fibroblast were obtained by tumor primary tissue cultures
as by previously published [93].
PCa-derived cells. Primary PCa cultures were derived from freshly-
explanted tissue specimens (PCa-derived ex vivo model) following
immortalization and phenotypic characterization. Clinical data and out-
come of patients were collected for 15 years [66]. Briefly, poor prognosis
group of donor patients with clinically localized PCa was defined by the
presence of biochemical/local recurrence, metastasis, or disease-specific
mortality, while the good prognosis group was defined by complete
remission after surgery alone. Prognostic signature “Bad versus Good
Prognosis profiling” was obtained in PCa cells by Affymetrix array (Human
U133A Gene ChIP platform) using PCa cells derived from patients with
different progression of disease (recurrent versus non-recurrent disease).
Regulated biological processes were identified by the GOAL Web-based
application and Gene Ontology (GO) terms with p < 0.01 considered
differentially regulated (false discovery rate = 0.013).
Affymetrix data analysis. Affymetrix Gene Chip scanning was analyzed by
customized R language-based script [88] using Bioconductor (http://www.
bioconductor.org) for quality-control analysis, data normalization, hier-
archical clustering, and identification of differentially expressed transcripts.
Biological processes and molecular functions involved were identified by
the GOAL Web-based application and the Unigene Build 154 according to
the Gene Ontology (GO; http://www.geneontology.org) Consortium
classification. Genes reported with p < 0.01 were considered differentially
regulated (false discovery rate= 0.013 [65, 66]).
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